References
- Adams, V., M. Murphy, and A. E. Clarke. 2009. “Anticipation: Technoscience, Life, Affect, Temporality.” Subjectivity 28 (1): 246–265. doi: https://doi.org/10.1057/sub.2009.18
- Albert, M. S., S. T. DeKosky, D. Dickson, B. Dubois, H. H. Feldman, N. C. Fox, A. Gamst, et al. 2011. “The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations From the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease.” Alzheimer’s & Dementia : the Journal of the Alzheimer’s Association 7 (3): 270–279. doi: https://doi.org/10.1016/j.jalz.2011.03.008
- Armstrong, D. 2019. “Diagnosis: From Classification to Prediction.” Social Science & Medicine 237: 112444. doi: https://doi.org/10.1016/j.socscimed.2019.112444
- Arribas-Ayllon, M. 2011. “The Ethics of Disclosing Genetic Diagnosis for Alzheimer’s Disease: Do We Need a New Paradigm?” British Medical Bulletin 100 (1): 7–21. doi: https://doi.org/10.1093/bmb/ldr023
- Ballenger, J. 2006. Self, Senility, and Alzheimer’s Disease in Modern America: A History. Baltimore, MD: Johns Hopkins University Press.
- Beard, R. 2016. Living with Alzheimer’s: Managing Memory Loss, Identity, and Illness. New York: NYU Press.
- Bemelmans, S. A. S. A., K. Tromp, E. M. Bunnik, R. J. Milne, S. Badger, C. Brayne, M. H. Schermer, and E. Richard. 2016. “Psychological, Behavioral and Social Effects of Disclosing Alzheimer’s Disease Biomarkers to Research Participants – a Systematic Review.” Alzheimer’s Research & Therapy 8 (46): 46. doi: https://doi.org/10.1186/s13195-016-0212-z
- Boenink, M. 2018. “Gatekeeping and Trailblazing: The Role of Biomarkers in Novel Guidelines for Diagnosing Alzheimer’s Disease.” BioSocieties 13 (1): 213–231. doi: https://doi.org/10.1057/s41292-017-0065-0
- Boenink, M., H. Van Lente, and E. Moors, eds. 2016. Emerging Technologies for Diagnosing Alzheimer’s Disease: Innovating with Care. London: Palgrave Macmillan.
- Chilibeck, G., M. Lock, and M. Sehdev. 2011. “Postgenomics, Uncertain Futures, and the Familiarization of Susceptibility Genes.” Social Science & Medicine 72 (11): 1768–1775. doi: https://doi.org/10.1016/j.socscimed.2010.01.053
- Corner, L., and J. Bond. 2004. “Being at Risk of Dementia: Fears and Anxieties of Older Adults.” Journal of Aging Studies 18 (2): 143–155. doi: https://doi.org/10.1016/j.jaging.2004.01.007
- Davis, D. S. 2017. “Ethical Issues in Alzheimer’s Disease Research Involving Human Subjects. Journal of Medical Ethics.” Institute of Medical Ethics 43 (12): 852–856. doi: https://doi.org/10.1136/medethics-2016-103392
- Dheensa, S., G. Samuel, A. M. Lucassen, and B. Farsides. 2018. “Towards a National Genomics Medicine Service: the Challenges Facing Clinical-Research Hybrid Practices and the Case of the 100 000 Genomes Project. Journal of Medical Ethics.” Institute of Medical Ethics 44 (6): 397–403. doi: https://doi.org/10.1136/medethics-2017-104588
- Gardner, J. 2017. Rethinking the Clinical Gaze: Patient-Centred Innovation in Paediatric Neurology. London: Palgrave Macmillan.
- Green, R. C., J. S. Roberts, L. A. Cupples, N. R. Relkin, P. J. Whitehouse, T. Brown, S. L. Eckert, et al. 2009. “Disclosure of APOE Genotype for Risk of Alzheimer’s Disease.” The New England Journal of Medicine 361 (3): 245–254. doi: https://doi.org/10.1056/NEJMoa0809578
- Harkins, K., P. Sankar, R. Sperling, J. D. Grill, R. C. Green, K. A. Johnson, M. Healy, and J. Karlawish. 2015. “Development of a Process to Disclose Amyloid Imaging Results to Cognitively Normal Older Adult Research Participants.” Alzheimer’s Research & Therapy 7 (1): 26. doi: https://doi.org/10.1186/s13195-015-0112-7
- Hedgecoe, A. 2004. The Politics of Personalised Medicine: Pharmacogenetics in the Clinic. Cambridge: Cambridge University Press.
- Hillman, A., and J. Latimer. 2019. “Somaticization, the Making and Unmaking of Minded Persons and the Fabrication of Dementia.” Social Studies of Science 49 (2): 208–226. doi: https://doi.org/10.1177/0306312719834069
- Jack, C. R., D. A. Bennett, K. Blennow, M. C. Carrillo, B. Dunn, S. B. Haeberlein, D. M. Holtzman, et al. 2018. “NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease.” Alzheimer’s & Dementia 14 (4): 535–562. doi: https://doi.org/10.1016/j.jalz.2018.02.018
- Jack, C. R., D. S. Knopman, W. J. Jagust, R. C. Petersen, M. W. Weiner, P. S. Aisen, L. M. Shaw, et al. 2013. “Tracking Pathophysiological Processes in Alzheimer’s Disease: An Updated Hypothetical Model of Dynamic Biomarkers.” Lancet Neurology 12 (2): 207–216. NIH Public Access doi: https://doi.org/10.1016/S1474-4422(12)70291-0
- Jack, C. R., D. S. Knopman, W. J. Jagust, L. M. Shaw, P. S. Aisen, M. W. Weiner, R. C. Petersen, and J. Q. Trojanowski. 2010. “Hypothetical Model of Dynamic Biomarkers of the Alzheimer’s Pathological Cascade.” Lancet Neurology 9 (1): 119. doi: https://doi.org/10.1016/S1474-4422(09)70299-6
- Keuck, L. 2018. “History as a Biomedical Matter: Recent Reassessments of the First Cases of Alzheimer’s Disease.” History and Philosophy of the Life Sciences 40 (1): 10. doi: https://doi.org/10.1007/s40656-017-0177-7
- Latimer, J. 2018. “Repelling Neoliberal World-Making? How the Ageing–Dementia Relation is Reassembling the Social.” The Sociological Review 66 (4): 832–856. doi: https://doi.org/10.1177/0038026118777422
- Leibing, A., and A. Kampf. 2013. “Neither Body nor Brain: Comparing Preventive Attitudes to Prostate Cancer and Alzheimer’s Disease.” Body & Society 19 (4): 61–91. doi: https://doi.org/10.1177/1357034X13477163
- Lock, M. 2013. The Alzheimer Conundrum: Entanglements of Dementia and Aging. Princeton, NJ: Princeton University Press.
- Lock, M., S. Lloyd, and J. Prest. 2006. “Genetic Susceptibility and Alzheimer’s Disease.” In Thinking About Dementia: Culture, Loss and the Anthropology of Senility, edited by A. Leibing and L. Cohen, 123–156. Brunswick, NJ: Rutgers University Press.
- Massumi, B. 2007. “Potential Politics and the Primacy of Preemption.” Theory and Event 10: 2.
- Milne, R. 2018. “From People with Dementia to People with Data: Participation and Value in Alzheimer’s Disease Research.” Biosocieties 13 (3): 623–639. doi: https://doi.org/10.1057/s41292-017-0112-x
- Milne, R. 2019. “The Rare and the Common: Scale and the Genetic Imaginary in Alzheimer's Disease Drug Development.” New Genetics and Society. Online ahead of print, doi:10.1080/14636778.2019.1637718.
- Milne, R., A. Diaz, S. Badger, E. Bunnik, K. Fauria, and K. Wells. 2018. “At, with and Beyond Risk: Expectations of Living with the Possibility of Future Dementia.” Sociology of Health & Illness 40 (6): 969–987. doi:10.1111/1467-9566.12731.
- Moreira, T., J. C. Hughes, T. Kirkwood, C. May, I. McKeith, and J. Bond. 2008. “What Explains Variations in the Clinical use of Mild Cognitive Impairment (MCI) as a Diagnostic Category?” International Psychogeriatrics 20 (04): 697–709. doi: https://doi.org/10.1017/S1041610208007126
- Moreira, T., C. May, and J. Bond. 2009. “Regulatory Objectivity in Action: Mild Cognitive Impairment and the Collective Production of Uncertainty.” Social Studies of Science 39 (5): 665–690. doi: https://doi.org/10.1177/0306312709103481
- Mozersky, J., P. Sankar, K. Harkins, S. Hachey, and J. Karlawish. 2017. “Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.” JAMA Neurology 75 (1): 44–50.
- Müller, R., C. Hanson, M. Hanson, M. Penkler, G. Samaras, L. Chiapperino, J. Dupré, et al. 2017. “The Biosocial Genome?” EMBO Reports 18 (10): 1677–1682. doi: https://doi.org/10.15252/embr.201744953
- OECD. 2015. “Enhancing Translational Research and Clinical Development for Alzheimer’s Disease and other Dementias.” OECD Science, Technology and Industry Policy Papers, Paris: OECD Publishing.
- Pickersgill, M., J. Niewöhner, R. Müller, P. Martin, and S. Cunningham-Burley. 2013. “Mapping the New Molecular Landscape: Social Dimensions of Epigenetics.” New Genetics and Society 32 (4): 429–447. doi: https://doi.org/10.1080/14636778.2013.861739
- Post, S. G. 2000. The Moral Challenge of Alzheimer Disease: Ethical Issues From Diagnosis to Dying. Baltimore: Johns Hopkins University Press.
- Reardon, J. 2017. The Postgenomic Condition: Ethics, Justice, and Knowledge after the Genome. Chicago: University of Chicago Press.
- Richardson, S., and H. Stevens. 2015. “Approaching Postgenomics.” In Postgenomics: Perspectives on Biology after the Genome, edited by S. Richardson and H. Stevens, 232–241. Durham, NC: Duke University Press.
- Robertson, A. 1990. “The Policies of Alzheimer’s Disease: A Case Study in Apocalyptic Demography.” International Journal of Health Services 20 (3): 429–442. doi: https://doi.org/10.2190/C8AE-NYC1-2R98-MHP1
- Sperling, R. A., P. S. Aisen, L. A. Beckett, D. A. Bennett, S. Craft, A. M. Fagan, T. Iwatsubo, et al. 2011a. “Toward Defining the Preclinical Stages of Alzheimer’s Disease: Recommendations From the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease.” Alzheimer’s & Dementia 7 (3): 280–292. doi: https://doi.org/10.1016/j.jalz.2011.03.003
- Sperling, R. A., C. R. Jack, P. S. Aisen, and P. S. Aisen. 2011b. “Testing the Right Target and Right Drug at the Right Stage.” Science Translational Medicine 3 (111): 111c. m33. NIH Public Access doi: https://doi.org/10.1126/scitranslmed.3002609
- Tsing, A. L. 2012. “On Nonscalability: The Living World Is Not Amenable to Precision-Nested Scales.” Common Knowledge 18 (3): 505–524. doi: https://doi.org/10.1215/0961754X-1630424
- Wienroth, M., C. Pearce, and C. McKevitt. 2019. “Research Campaigns in the UK National Health Service: Patient Recruitment and Questions of Valuation.” Sociology of Health & Illness 41 (7): 1444–1461. doi: https://doi.org/10.1111/1467-9566.12957
- Williams, S. J., P. Higgs, and S. Katz. 2012. “Neuroculture, Active Ageing and the ‘Older Brain’: Problems, Promises and Prospects.” Sociology of Health & Illness 34 (1): 64–78. doi: https://doi.org/10.1111/j.1467-9566.2011.01364.x